Orphazyme CEO disappointed with failed ALS trial – pins hope on other disease area
Christophe Bourdon, Orphazyme's new CEO, is candid about the group's main candidate against ALS, arimoclomol, came out of its phase-3 trial with weak results.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN & CATHERINE BRETT
It's disappointing that Orphazyme's main treatment candidate,against amyotrophic lateral sclerosis, arimoclomol, did not meet expectations in its phase III trial, Chief Executive Christophe Bourdon tells MedWatch after the news emerged Friday that the product has not been able to fulfill neither the primary nor secondary criteria in the crucial phase III trial.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
